Navigation Links
Agilis Biotherapeutics and Intrexon to Pursue Transformative Therapies for Rare Genetic Disease
Date:12/31/2013

synthetic biology approach and integrated technologies Better DNA®, and we invite you to discover more www.DNA.com.

Trademarks
Intrexon, UltraVector, RheoSwitch Therapeutic System, RTS and Better DNA are trademarks of Intrexon and/or its affiliates.  Other names may be trademarks of their respective owners.

Safe Harbor Statement
Some of the statements made in this press release are forward-looking statements.  These forward-looking statements are based upon our current expectations and projections about future events and generally relate to our plans, objectives and expectations for the development of our business.  Although management believes that the plans and objectives reflected in or suggested by these forward-looking statements are reasonable, all forward-looking statements involve risks and uncertainties and actual future results may be materially different from the plans, objectives and expectations expressed in this press release.

For more information contact:

Agilis Biotherapeutics
George Zorich
Chief Executive Officer
Email:  info@agilisbio.com

Intrexon Corporation
Peter McLaughlin
Vice President Corporate Communications
Tel:      +1 (561) 410-7023
Email:  PublicRelations@intrexon.com


'/>"/>
SOURCE Intrexon Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Healthpoint Biotherapeutics to Present at 30th Annual J.P. Morgan Healthcare Conference
2. Oxford BioTherapeutics Appoints C. Glenn Begley as a Senior Clinical Advisor and Non-executive Director
3. Healthpoint Biotherapeutics To Create State-of-the-Art Cell Sciences Manufacturing Facility
4. Northwest Biotherapeutics Appoints Pharma Industry Veteran As CEO Of German Subsidiary
5. Smith & Nephew Announces Agreement To Acquire Assets Of Healthpoint Biotherapeutics
6. Genedata Expressionist for Mass Spectrometry Showcased at 2013 Biotherapeutics Analytical Summit
7. Oxford BioTherapeutics and Boehringer Ingelheim Enter Collaboration to Discover Novel Antibody Targets in Cancer
8. Acquisitions, Project Announcements & Trend Analysis News for Oxygen Biotherapeutics, Glu Mobile, Cisco Systems, Barrick Gold, CVS Caremark
9. Northwest Biotherapeutics Announces Pricing Of Public Offering Of Common Stock And Warrants
10. Northwest Biotherapeutics to Present at the Oppenheimer 24th Annual Healthcare Conference On December 10, 2013
11. Synthetic Biologics and Intrexon Corporation Enter Worldwide Exclusive Collaboration for Infectious Diseases
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... 10, 2014 Research and Markets ( ... "International Photonic Integrated Circuit (Monolithic Integration, Hybrid ... report to their offering. ... of photonic integration traces its roots in the ... of photonic integration went unexplored and unfulfilled for ...
(Date:7/10/2014)... to the International Atomic Energy Agency (IAEA) the ... acquiring sufficient quantities of plutonium or highly enriched ... device. The IAEA also notes that most cases ... which can be challenging to detect with most ... appearing this week in the Journal of ...
(Date:7/10/2014)... D.C., June 17, 2014 Using microscopic polymer ... specific gases, researchers at MIT,s Quantum Photonics Laboratory ... levels in the parts-per-billion range. Optical sensors are ... their high signal-to-noise ratio, compact, lightweight nature, and ... gas sensors had been developed before, the MIT ...
(Date:7/10/2014)... basis of psychiatric disorders has been extremely challenging because ... but are insufficient to cause disease. Now investigators reporting ... journal Cell Stem Cell describe a strategy ... interact with other risk factors or environmental exposures to ... pinpoints a genetic variant that may predispose individuals to ...
Breaking Biology Technology:International Photonic Integrated Circuit (Monolithic Integration, Hybrid Integration, Module Integration) Market - Forecasts to 2019 2Sensitive detection method may help impede illicit nuclear trafficking 2Swell new sensors 2New strategy could uncover genes at the root of psychiatric illnesses 2
... Pa., Feb. 23 Endo Pharmaceuticals (Nasdaq: ENDP ... by its wholly owned subsidiary, BTB Purchaser Inc., for all ... Inc. (Nasdaq: IDEV ). American Stock Transfer & ... Endo that, as of 5:00 p.m., New York City time, ...
... Calif., Feb. 23 WaferGen Biosystems,Inc. (OTC ... state-of-the-art gene,expression, genotyping, cell biology and stem ... results of the company,s SmartChip Real-Time PCR,System ... 16th,International Molecular Medicine Tri-Conference. The data ...
... Micromet, Inc. (Nasdaq: MITI ), a biopharmaceutical ... cancer, inflammation and autoimmune diseases, today announced that Dr. ... as of February 18, 2009. As a result of ... nine members.Dr. Dhingra has been active in oncology clinical ...
Cached Biology Technology:Endo Pharmaceuticals Successfully Completes Tender Offer for Shares of Indevus Pharmaceuticals and Announces Subsequent Offering Period 2Endo Pharmaceuticals Successfully Completes Tender Offer for Shares of Indevus Pharmaceuticals and Announces Subsequent Offering Period 3Data on WaferGen's SmartChip Real-Time PCR System(TM) to be Presented at 16th International Molecular Medicine Tri-Conference 2Data on WaferGen's SmartChip Real-Time PCR System(TM) to be Presented at 16th International Molecular Medicine Tri-Conference 3Micromet Adds Former Head of Roche Oncology Kapil Dhingra, MD to Board of Directors 2Micromet Adds Former Head of Roche Oncology Kapil Dhingra, MD to Board of Directors 3Micromet Adds Former Head of Roche Oncology Kapil Dhingra, MD to Board of Directors 4Micromet Adds Former Head of Roche Oncology Kapil Dhingra, MD to Board of Directors 5
(Date:7/11/2014)... spider toxins to study the proteins that let nerve ... they have stumbled upon a biological tactic that may ... plagues in a safe and environmentally responsible way. ... lethal for one species and harmless for a closely ... specific pests without harming beneficial species like bees. A ...
(Date:7/10/2014)... 2014  Aware, Inc. (NASDAQ: AWRE ), ... announced on June 26, 2014 that its Board of ... per share, or approximately $40 million in total.  The ... and a payment date of July 24, 2014.  The ... set an ex-dividend date for this special cash dividend. ...
(Date:7/10/2014)... According to the new market research report, ... (Optical Prism, Pizeoelectric, Capacitive, and Adhesives), Application (Mobile Devices, ... and Geography - Global Trends & Forecasts to 2014 ... Market is projected to cross $14.35 Billion by 2020, ... to 2020. Browse more than 78 market ...
Breaking Biology News(10 mins):Potent spider toxin 'electrocutes' German, not American, cockroaches 2Potent spider toxin 'electrocutes' German, not American, cockroaches 3NASDAQ Sets Ex-Dividend Date for Aware, Inc.'s Special Cash Dividend of $1.75 Per Share 2Fingerprint Sensors Market worth $14.35 Billion by 2020 2Fingerprint Sensors Market worth $14.35 Billion by 2020 3
... Researchers at the Buck Institute for Age Research ... to treat rodents afflicted with Parkinson,s Disease (PD). ... same group had previously developed, can be used to ... disease and paves the way for the use of ...
... AUGUSTA, Ga. Children at risk for diabetes before they ... bones, Medical College of Georgia researchers report. A study ... exercise found that the 30 percent with signs of poor ... measure of bone strength, said Dr. Norman Pollock, bone biologist ...
... that RNA plays a major role in cell biology, ranging ... as an important tool in functional genomics. Now WIREs RNA, ... providing RNA experts and researchers not only with a title ... to generate new insights and applications. "In the 10 ...
Cached Biology News:Scientists successfully use human induced pluripotent stem cells to treat Parkinson's in rodents 2Diabetes risk in children increases risk for weak bones 2
Compound(s) tested through a broad panel of 38 ligand binding and enzyme assays targeting the Central Nervous System. Used to determine selecitivty and potential CNS-Side Effect liabilities of compo...
... tested through 63 ligand ... spanning a broad therapeutic ... includes many non human ... non-selective assays. Used ...
... Receptor (PR) Competitor Assay Kits are ... progesterone receptor binding compounds using fluorescence ... a fusion of glutathione transferase to ... progesterone receptor [PR-LBD(GST)] and a proprietary, ...
... is critical to the maintenance of ... proteins as important and diverse as ... shock and stress response, antigen presentation, ... ion channels, cell cycle regulation, transcription, ...
Biology Products: